Eur Arch Otorhinolaryngol:顺铂化疗对内耳功能和血清prestin浓度的影响

2021-07-18 AlexYang MedSci原创

顺铂是一种化疗烷化剂,对治疗不同的恶性肿瘤如头/颈部、肺、膀胱、宫颈、卵巢、睾丸和胃肠系统癌症非常有效。其主要副作用之一是不可逆的感音神经性听力损失(SNHL),大约62%的患者会出现这种情况。

顺铂是一种化疗烷化剂,对治疗不同的恶性肿瘤如头/颈部、肺、膀胱、宫颈、卵巢、睾丸和胃肠系统癌症非常有效。其主要副作用之一是不可逆的感音神经性听力损失(SNHL),大约62%的患者会出现这种情况。

由于顺铂化疗的主要副作用之一是不可逆转的感音神经性听力损失,近期,有研究人员评估了血清prestin浓度作为潜在的耳蜗生物标志物与顺铂化疗后患者的听觉发现之间的相关性情况

该前瞻性研究共包括52名18-75岁的患者。所有受试者都是从一家三级医院的放疗和肿瘤中心招募的。在基线和1-3周的化疗后评估了听力参数,测量了血清prestin的浓度。内耳功能通过纯音测听(PTA)和耳声发射畸变产物(DPOAE)进行评估。研究人员还进行重复测量方差分析评估了PTA、DPOAE、血清prestin浓度和顺铂累积剂量之间的关系。

研究共有52名患者(36名女性)参加。PTA结果显示,耳毒性在顺铂累积剂量高的患者中更为常见(χ2趋势=15.25;P<0.001)。DPOAE反应显示,38.5%的患者在接受40-80mg顺铂给药后出现耳毒性改变。在接受40-80毫克顺铂后,血清prestin浓度从130增加到230pg/ml。接受顺铂80毫克以上后,prestin浓度与DPOAE反应的耳毒性变化有明显的正相关关系。

不同剂量顺铂中DPOAE反应的耳毒性变化情况

综上所述,研究显示prestin浓度与DPOAE诊断的耳毒性之间存在相关性。prestin浓度的早期上升特别重要,且是听力损失的早期信号。建议今后的研究调查不同剂量的顺铂对prestin浓度的影响以及耳毒性和临床病理特征之间的相关性

原始出处:

Mir Mohammad Jalali , Hamid Saeidi Saedi , Farshid Saadat. Effect of cisplatin chemotherapy on the inner ear function and serum prestin concentration. Eur Arch Otorhinolaryngol. Jul 2021

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1737711, encodeId=99401e377112e, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Wed Aug 18 10:37:40 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051671, encodeId=a2ae20516e1fa, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Thu Aug 19 18:37:40 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490083, encodeId=a0c414900835b, content=<a href='/topic/show?id=bf08965e9a7' target=_blank style='color:#2F92EE;'>#铂化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96579, encryptionId=bf08965e9a7, topicName=铂化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67238689175, createdName=drj2006, createdTime=Tue Jul 20 12:37:40 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544691, encodeId=7ec7154469171, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue Jul 20 12:37:40 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000727, encodeId=3f641000e27c5, content=有研究人员评估了血清prestin浓度作为潜在的耳蜗生物标志物与顺铂化疗后患者的听觉发现之间的相关性情况。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd984965877, createdName=1453df99m58暂无昵称, createdTime=Sun Jul 18 23:11:28 CST 2021, time=2021-07-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1737711, encodeId=99401e377112e, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Wed Aug 18 10:37:40 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051671, encodeId=a2ae20516e1fa, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Thu Aug 19 18:37:40 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490083, encodeId=a0c414900835b, content=<a href='/topic/show?id=bf08965e9a7' target=_blank style='color:#2F92EE;'>#铂化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96579, encryptionId=bf08965e9a7, topicName=铂化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67238689175, createdName=drj2006, createdTime=Tue Jul 20 12:37:40 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544691, encodeId=7ec7154469171, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue Jul 20 12:37:40 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000727, encodeId=3f641000e27c5, content=有研究人员评估了血清prestin浓度作为潜在的耳蜗生物标志物与顺铂化疗后患者的听觉发现之间的相关性情况。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd984965877, createdName=1453df99m58暂无昵称, createdTime=Sun Jul 18 23:11:28 CST 2021, time=2021-07-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1737711, encodeId=99401e377112e, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Wed Aug 18 10:37:40 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051671, encodeId=a2ae20516e1fa, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Thu Aug 19 18:37:40 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490083, encodeId=a0c414900835b, content=<a href='/topic/show?id=bf08965e9a7' target=_blank style='color:#2F92EE;'>#铂化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96579, encryptionId=bf08965e9a7, topicName=铂化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67238689175, createdName=drj2006, createdTime=Tue Jul 20 12:37:40 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544691, encodeId=7ec7154469171, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue Jul 20 12:37:40 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000727, encodeId=3f641000e27c5, content=有研究人员评估了血清prestin浓度作为潜在的耳蜗生物标志物与顺铂化疗后患者的听觉发现之间的相关性情况。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd984965877, createdName=1453df99m58暂无昵称, createdTime=Sun Jul 18 23:11:28 CST 2021, time=2021-07-18, status=1, ipAttribution=)]
    2021-07-20 drj2006
  4. [GetPortalCommentsPageByObjectIdResponse(id=1737711, encodeId=99401e377112e, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Wed Aug 18 10:37:40 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051671, encodeId=a2ae20516e1fa, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Thu Aug 19 18:37:40 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490083, encodeId=a0c414900835b, content=<a href='/topic/show?id=bf08965e9a7' target=_blank style='color:#2F92EE;'>#铂化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96579, encryptionId=bf08965e9a7, topicName=铂化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67238689175, createdName=drj2006, createdTime=Tue Jul 20 12:37:40 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544691, encodeId=7ec7154469171, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue Jul 20 12:37:40 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000727, encodeId=3f641000e27c5, content=有研究人员评估了血清prestin浓度作为潜在的耳蜗生物标志物与顺铂化疗后患者的听觉发现之间的相关性情况。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd984965877, createdName=1453df99m58暂无昵称, createdTime=Sun Jul 18 23:11:28 CST 2021, time=2021-07-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1737711, encodeId=99401e377112e, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Wed Aug 18 10:37:40 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051671, encodeId=a2ae20516e1fa, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Thu Aug 19 18:37:40 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490083, encodeId=a0c414900835b, content=<a href='/topic/show?id=bf08965e9a7' target=_blank style='color:#2F92EE;'>#铂化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96579, encryptionId=bf08965e9a7, topicName=铂化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67238689175, createdName=drj2006, createdTime=Tue Jul 20 12:37:40 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544691, encodeId=7ec7154469171, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue Jul 20 12:37:40 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000727, encodeId=3f641000e27c5, content=有研究人员评估了血清prestin浓度作为潜在的耳蜗生物标志物与顺铂化疗后患者的听觉发现之间的相关性情况。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd984965877, createdName=1453df99m58暂无昵称, createdTime=Sun Jul 18 23:11:28 CST 2021, time=2021-07-18, status=1, ipAttribution=)]
    2021-07-18 1453df99m58暂无昵称

    有研究人员评估了血清prestin浓度作为潜在的耳蜗生物标志物与顺铂化疗后患者的听觉发现之间的相关性情况。。

    0

相关资讯

Br J Cancer:berzosertib+吉西他滨±顺铂联合治疗晚期实体瘤

包括铂类药物和吉西他滨(gemcitabine)在内的化疗药物会在癌细胞中诱导潜在的致命的DNA损伤反应(DDR),这是许多癌症标准疗法的一部分。

Br J Cancer:Berzosertib联合顺铂治疗晚期实体瘤患者的临床研究

用于治疗多种肿瘤的标准护理疗法主要包括DNA损伤相关的化疗药物。

Sci Rep:治疗顺铂诱导的听力损失的新靶标

G蛋白信号调节因子(RGS)提高了G蛋白的GTP酶活性,使G蛋白偶联受体(GPCRs)引发的信号快速终止。几个GPCRs的激活,包括大麻素受体2(CB2R)和腺苷A1受体(A1AR),可以预防噪音和药

Lancet oncol:卡瑞珠单抗+吉西他滨+顺铂或可成为中国复发/转移性鼻咽癌的新标准一线疗法

卡瑞珠单抗组联合吉西他滨和顺铂或可成为复发性或转移性鼻咽癌患者的新标准一线治疗方案

JCO:3期临床试验| 吉西他滨+顺铂联合贝伐单抗治疗晚期尿路上皮癌

在GC方案中加入贝伐单抗并不能改善转移性尿路上皮癌患者的总生存期

Clin Cancer Res:局部进展期鼻咽癌患者顺铂两种不同给药方式治疗的疗效和安全性评估:随机对照临床研究

在局部进展期鼻咽癌治疗中,顺铂每3周1次(100 mg/m 2)联合放疗不劣于每周1次(40 mg/m 2)。并且每3周1次给药的严重急性毒性反应以及迟发性的听力下降较少。